Literature DB >> 8525368

Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.

J Wagner1, R A Lerner, C F Barbas.   

Abstract

Antibodies that catalyze the aldol reaction, a basic carbon-carbon bond-forming reaction, have been generated. The mechanism for antibody catalysis of this reaction mimics that used by natural class I aldolase enzymes. Immunization with a reactive compound covalently trapped a Lys residue in the binding pocket of the antibody by formation of a stable vinylogous amide. The reaction mechanism for the formation of the covalent antibody-hapten complex was recruited to catalyze the aldol reaction. The antibodies use the epsilon-amino group of Lys to form an enamine with ketone substrates and use this enamine as a nascent carbon nucleophile to attack the second substrate, an aldehyde, to form a new carbon-carbon bond. The antibodies control the diastereofacial selectivity of the reaction in both Cram-Felkin and anti-Cram-Felkin directions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525368     DOI: 10.1126/science.270.5243.1797

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  76 in total

1.  Catalytic and binding poly-reactivities shared by two unrelated proteins: The potential role of promiscuity in enzyme evolution.

Authors:  L C James; D S Tawfik
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

2.  Synthesis of an organoinsulin molecule that can be activated by antibody catalysis.

Authors:  D S Worrall; J E McDunn; B List; D Reichart; A Hevener; T Gustafson; C F Barbas; R A Lerner; J M Olefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

3.  Enzyme-like proteins by computational design.

Authors:  D N Bolon; S L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

4.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

5.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

6.  Structural evidence for substrate strain in antibody catalysis.

Authors:  Jun Yin; Scott E Andryski; Albert E Beuscher; Raymond C Stevens; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

7.  Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.

Authors:  Subhash C Sinha; Lian-Sheng Li; Gregory P Miller; Shantanu Dutta; Christoph Rader; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

8.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

9.  Evaluation and ranking of enzyme designs.

Authors:  Gert Kiss; Daniela Röthlisberger; David Baker; K N Houk
Journal:  Protein Sci       Date:  2010-09       Impact factor: 6.725

10.  Impact of temperature on the time required for the establishment of primordial biochemistry, and for the evolution of enzymes.

Authors:  Randy B Stockbridge; Charles A Lewis; Yang Yuan; Richard Wolfenden
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.